PREPRINT (not peer reviewed)

Psilocybin prevents activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: bioRxiv
Date: 2023-12-13
Source: bioRxiv
DOI: 10.1101/2023.12.12.571374
PubMed: Unavailable

Authors

Conn K Milton L Huang K Munguba H Ruuska J Lemus M Greaves E Homman-Ludiye J Oldfield B Foldi C.

Watch author

Derived topics and classifications

psilocybin Depression Eating Disorders Mechanism of Action Receptor Pharmacology Clinical Trial Animal Study Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-08-17 Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord InjuryClinicalTrials.gov · 2026-08-10 Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-07-30 PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-07-21 Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled TrialClinicalTrials.gov · 2026-07-14 PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10